Healthcare provider profile · identity verified

Nicholas A Fredette, DNP

Nurse Practitioner · BURLINGTON, VT · NPI 1710469481

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Eliquis	Apixaban	203	31
Amlodipine Besylate	Amlodipine Besylate	140	31
Atorvastatin Calcium	Atorvastatin Calcium	112	30
Metoprolol Succinate	Metoprolol Succinate	94	19
Levothyroxine Sodium	Levothyroxine Sodium	78	21
Losartan Potassium	Losartan Potassium	78	22
Lisinopril	Lisinopril	77	19
Omeprazole	Omeprazole	70	29
Furosemide	Furosemide	66	16
Sertraline Hcl	Sertraline Hcl	62	16
Gabapentin	Gabapentin	59	25
Torsemide	Torsemide	51	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	51	29
Rosuvastatin Calcium	Rosuvastatin Calcium	49	17
Simvastatin	Simvastatin	48	suppressed
Duloxetine Hcl	Duloxetine Hcl	45	12
Donepezil Hcl	Donepezil Hcl	44	suppressed
Methocarbamol	Methocarbamol	41	20
Prednisone	Prednisone	41	22
Xarelto	Rivaroxaban	41	suppressed
Morphine Sulfate	Morphine Sulfate	39	13
Hydrochlorothiazide	Hydrochlorothiazide	38	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	37	suppressed
Trazodone Hcl	Trazodone Hcl	36	11
Jardiance	Empagliflozin	35	suppressed
Propranolol Hcl	Propranolol Hcl	35	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	34	suppressed
Diclofenac Sodium	Diclofenac Sodium	34	16
Cephalexin	Cephalexin	33	26
Oxycodone Hcl	Oxycodone Hcl	32	11
Meloxicam	Meloxicam	31	suppressed
Spironolactone	Spironolactone	30	suppressed
Lorazepam	Lorazepam	29	16
Olanzapine	Olanzapine	27	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	27	24
Soaanz	Torsemide	27	suppressed
Celecoxib	Celecoxib	25	11
Galantamine Er	Galantamine Hbr	25	suppressed
Potassium Chloride	Potassium Chloride	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	suppressed
Clonazepam	Clonazepam	24	suppressed
Myrbetriq	Mirabegron	24	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	17
Alendronate Sodium	Alendronate Sodium	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	11
Valsartan	Valsartan	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	21
Finasteride	Finasteride	22	suppressed
Warfarin Sodium	Warfarin Sodium	22	suppressed
Bupropion Xl	Bupropion Hcl	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	21	19
Pantoprazole Sodium	Pantoprazole Sodium	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Atenolol	Atenolol	20	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	20	18
Erythromycin	Erythromycin Base	17	11
Latanoprost	Latanoprost	17	suppressed
Memantine Hcl Er	Memantine Hcl	17	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	17	suppressed
Colchicine	Colchicine	16	suppressed
Azithromycin	Azithromycin	15	14
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	15	suppressed
Belsomra	Suvorexant	14	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Mirtazapine	Mirtazapine	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Dayvigo	Lemborexant	13	suppressed
Digoxin	Digoxin	13	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	11	suppressed
Doxepin Hcl	Doxepin Hcl	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Midodrine Hcl	Midodrine Hcl	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Rasagiline Mesylate	Rasagiline Mesylate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error